20 years of nephrologist‘s journey into the depths of phosphorus toxicity

Czech version

Authors: Sylvie Dusilová Sulková ^1,2
Authors‘ workplace: Hemodialyzační středisko FN Hradec Králové ¹; Katedra interních oborů LF UK Praha, pracoviště Hradec Králové ²
Published in: Vnitř Lék 2020; 66(1): 44-50
Category:

Overview

This article focuses on phosphate toxicity in kidney disease and namely in kidney failure. Twenty years ago, the first article documenting the link between hyperphosphatemia and mortality, was published. Shortly after, the association between phosphate and cardiovascular complications in kidney failure was demonstrated. Phosphate itself plays an active role in vascular calcifications. It induces phenotypic changes in vascular smooth muscle cells giving rise a matrix with consequent phosphate and calcium accumulation. The body is fighting again phosphate load. Initially, these mechanisms are adaptive (PTH and FGF-23 elevation). In kidney failure, they become toxic. Dietary measures, gastrointestinal phosphate binders and dialysis elimination are used for correction of hyperphosphatemia. Despite all observations, experimental and clinical studies with many discoveries, the relation between mineral and bone disorder and cardiovascular damage, remains still not fully solved.

Keywords:

cardiovascular complications – FGF-23 – hyperphosphatemia – chronic kidney disease – mediocalcinosis – mineral and bone disorder (CKD-MBD) – phosphate – PTH

Sources

1. U.S. Renal Data System. USRDS 2018 Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2018. www.usrds.org

2. Cunningham J, Francesco Locatelli F et al. Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options. Clin J Am Soc Nephrol 2011; 6: 913–921.

3. Vervloet M, Sezer S, Massy ZA, et al. on behalf of the ERA-EDTA Working Group on Chronic Kidney Disease-Mineral and Bone Disorders and the European Renal Nutrition Working Group: The role of phosphate in kidney disease. Nat Rev Nephrol 2016; 13: 27–38.

4. Shefold JC, Filipatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: epidemiology, mechanism and management. Nat Rev Nephrol 2016; 12: 610–623.

5. Herzog CA, Asinger RW, Berger AK. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572–586.

6. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013; 382: 339–352.

7. Cozzolino M, Mangano M, Stucchi A, et al. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant 2018; 33(suppl. 3): iii28–iii34.

8. Lazarus JM, Lowrie EG, Hampers CL, et al. Cardiovascular disease in uremic patients on hemodialysis. Kidney Int 1995; Suppl. 2: 167–175.

9. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–617.

10. Amann K, Gross ML, London GM, et al. Hyperphosphatemia – a silent killer of patients with renal failure? Nephrol Dial Transplant 1999; 14: 2085–2087.

11. Brandenburg

12. Silver J, et al. FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol 2013; doi:10.1038/nrneph.2013.147

13. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 2008; 74: 276–288.

14. Týcová I, Sulková SD, Štěpánková J, et al. Molecular patterns of diffuse and nodular parathyroid hyperplasia in long-term hemodialysis. Am J Physiol Endocrinol Metab 2016; 311: E720–E729.

15. Silver J, Kilav R, Naveh-Many T Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2002; 283: F367–F376.

16. Komaba H, Fukagawa M Phosphate-a poison for humans? Kidney Int 2016; 90: 753–763.

17. Vanholder R, Argiles A, Baurmeister U, et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001; 24: 695–725.

18. Hyšpler R, Tichá A, Šafránek R, et al. Indoxyl Sulfate Elimination in Renal Replacement Therapy: Influence of Citrate- versus Acetate-Buffering Component during Bicarbonate Dialysis. Dis Markers 2018; 15: 3985–3986.

19. Ritter CS, Slatopolsky E Phosphate Toxicity in CKD: The Killer among Us. Clin J Am Soc Nephrol 2016; 11: 1088–1100.

20. Moe SM Calcium as a cardiovascular toxin in CKD-MBD. Bone 2017; 100: 94–99.

21. Lynch K, Lynch R, Curhan GC, et al. Prescribed dietary phosphate restriction and survival among hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 620–629.

22. Sekercioglu N, Thabane L, Diaz-Martinez JP, et al. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. PLoS One 2016; 11(6): e0156891.

23. Floege J. Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol 2016; 29: 329–340.

24. Isakova T, Ix JH, Sprague SM, et al. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. J Am Soc Nephrol 2015; 26: 2328–2339.

25. Mehta R, Isakova T Continued search for therapies to favourably modify phosphate and FGF-23 levels in CKD. Clin J Am Soc Nephrol 2017; 12: 1911–1913.

26. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int 2017; 92: 26–36.

27. Cozzolino M. CKD-MBD KDIGO guidelines: how difficult is reaching the “target”? Clin Kidney J 2018; 11: 70–72.

28. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl 2017; 7: 1–59.

29. Lopot F, Švára F, Polakovič . „Revival domácí dialýzy”. Aktuality v nefrologii 2018; 24: 46–55.

30. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945–1953.

31. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76: (Suppl. 113): S3–S130.

32. Brunerová L, Palicka V, Sulkova SD. Commentary on management of osteoporosis in advanced CKD: common view of a nephrologist and a bone specialist. Endocr Pract 2019; 25: 193–196.

33. Lau WL, Pai A, Moe SM, et al. Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis 2011; 18: 105–112.

34. Cozzolino M, Ciceri P, Galassi A. The Key Role of Phosphate on Vascular Calcification. Toxins 2019; 11: 213.

35. Disthabanchong S. Phosphate and cardiovascular disease beyond chronic kidney disease and vascular calcification. Int J Nephrology 2018; doi.org/10.1155/2018/3152806

36. Razzaque MS The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009; 5: 611–619.

37. Grabner A, Mazzaferro S, Cianciolo G. Fibroblast Growth Factor 23: Mineral Metabolism and Beyond. Contrib Nephrol 2017; 190: 83–95.

38. Rodriguez M, Lorenzo V. Parathyroid hormone, a uremic toxin. Semin Dial 2009; 22: 363–368.

39. Navarro-García JA, Fernández-Velasco M, Delgado C, et al. PTH, vitamin D, and the FGF-23-klotho axis and heart: Going beyond the confines of nephrology. Eur J Clin Invest 2018; 48: doi: 10.1111/eci.12902.

40. Gutiérrez OM, Mannstadt M, Isakova T. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584–592.

41. Agarwal I, Ide N, Ix JH. Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc 2014; 3: e000584.

42. Ho LY, Wong PN, Sin HK, et al. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol 2017; 18: 12.

43. Wang J, Zhou JJ, Robertson GR, et al. Vitamin D in Vascular Calcification: A Double-Edged Sword? Nutrients 2018; 10. pii: E652.

44. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med 2018; 378: 1704–1714.

45. Nigwekar SU, Kroshinsky D, Nazarian RM. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis 2015; 66: 133–146.